Respiratory Virus Infections in Pediatric and Adult Allogeneic Hematopoietic Cell Transplant Recipients
=======================================================================================================

In early prospective studies evaluating the incidence of respiratory viral infections in allogeneic HCT recipients conducted by two members of the European Group for Blood and Marrow Transplantation (EBMT), frequencies of these infections were determined at 4 and 7.1%, respectively. Furthermore, the highest mortality rates from fatal pneumonia were found with RSV of 60% and AdV of 75% ([@B99]). Today, 20 years on, these continue to be frequent infections and still contribute to significant mortality with rates ranging between 10 and 50% if infection progresses to the lower respiratory tract ([@B14]; [@B48]; [@B131]; [@B128]; [@B26]; [@B157]).

Human pathogenic viruses frequently causing respiratory infections in the allogeneic HCT setting include RSV, AdV, IFV, PIV, HMPV, RhV, HCoV, and HBoV ([@B132]; [@B2]). Such respiratory virus infections contribute to morbidity and mortality for a number of reasons. Firstly, HCT recipients suffer from prolonged immunosuppression and a lack of both humoral and T cell-mediated immunity impairs viral clearance ([@B88]; [@B140]). In addition, these patients are usually antibody-depleted and the strength of the conditioning regimen and the ongoing immunosuppressive therapy diminishes the antiviral immune response further. Moreover, the type of graft may have an impact on the immune response and pediatric HCT recipients may also be immunologically naïve because of their age. Secondly, viral factors shape the outcome. Respiratory viruses vary in their pathogenicity, i.e., they cause more severe disease compared with other viruses. Also, there is the capacity for certain strains of a given respiratory virus to display increased virulence as is the case with IFV and it is therefore important to identify viral and host genes that determine virulence. Thirdly, a limited number of effective antivirals or the emergence of drug resistance also hamper successful treatment. Finally, factors like persisting infections, co-infections and co-morbidities will also influence the outcome.

In contrast to immunocompetent individuals, HCT recipients present with prolonged viral shedding and have a higher rate of progression from URI to LRI ([@B26]; [@B34]; [@B84]). Increased viral loads and protracted infections raise the likelihood of progression that differs between viruses. URI has been commonly defined as laboratory-confirmed viral nasal wash or swab with pharyngitis, cough, otitis, nasal discharge and/or congestion in the absence of infiltrates on chest x-ray or computed tomography (CT) scan and hypoxemia, and LRI has been defined as laboratory-confirmed viral nasal wash or swab in the presence of infiltrates on chest x-ray or CT scan suggestive of a viral respiratory infection but not necessarily detection of viral nucleic acid in samples obtained from BAL ([@B149]). In HCT recipients, RSV is most frequently detected, followed by HMPV and PIV. In 5--50% of cases, these viruses progress to LRI, often complicate the transplant course by causing airflow obstruction or bronchiolitis obliterans and also increase the rate of mortality up to 50% ([@B26]). Several respiratory viruses share a number of risk factors associated with LRI occurrence. It is worth noting that CMV also represents an opportunistic pathogen that is causally related to pneumonia and LRI. However, CMV will not be discussed in this review since it is not primarily considered a respiratory virus. That said, CMV is a pathogen that frequently occurs as part of a simultaneous infection -- indeed a respiratory viral infection can often precede bacterial and fungal infections -- thus further complications associated with respiratory virus infections need to be acknowledged.

In this review, we will focus on respiratory virus infections and, particularly, those that are commonly detected after HCT. We highlight risk factors that facilitate progression from URI to LRI and discuss diagnostic approaches. Current treatment strategies along with new treatment options will be discussed.

Adenovirus
----------

Adenovirus is a member of the *adenoviridae* that circulates throughout the year. Currently, 90 human types are known which are further divided into seven species A--G^[1](#fn01){ref-type="fn"}^ (accessed on 20 August 2018). Alongside conjunctivitis and diarrhea, AdV can cause pharyngitis, bronchitis and pneumonia but also lethal hepatitis or severe bloody colitis. Pertinent to this review, AdV is a pathogen associated with severe complications in immunosuppressed pediatric HCT recipients including increased mortality ([@B96]; [@B53]; [@B98]; [@B52]; [@B69]). In adult patients, AdV infections are less commonly reported. However, it is possible this perception might be biased by reduced frequency of screening in adults. A study in adult allogeneic HCT recipients reported an infection rate of 2.5%. Pneumonia occurred in 24% of cases and was the most common cause of death associated with AdV ([@B184]). An important consideration is that AdV infections infrequently present with respiratory symptoms at the onset of infection; instead they are commonly detected by monitoring stool ([@B102]; [@B98]). Indeed, gastrointestinal shedding pre-transplant has been demonstrated to reflect increased risk of viremia after HCT ([@B90]).

Human Bocavirus
---------------

Human bocavirus was identified in 2005 as a human pathogen that causes respiratory tract infections in infants. It has been assigned to the *parvoviridae* and received its name because of sequence homology to two other members in the genus *Bocaparvovirus*, Bovine parvovirus infecting cattle and Canine minute virus infecting dogs ([@B6]). Currently, four HBoV variants have been described. Like HBoV3, HBoV1 can enter an episomal state, allowing the establishment of a persistent infection ([@B78]). Whereas HBoV2, HBoV3, and HBoV4 cause gastroenteritis and are genetically diverse, HBoV1 exhibits a stronger association with LRI than enteritis, often in conjunction with other respiratory pathogens, and has limited genetic diversity although reinfections with different variants occur ([@B7]; [@B42]; [@B8]; [@B79]; [@B176]; [@B103]). Symptoms following infection include cough, dyspnea, pharyngitis, bronchitis, pneumonia, and diarrhea. Several reports have suggested that HBoV1 can cause severe infections on its own and is not a mere bystander virus ([@B138]; [@B166]; [@B45]). Likewise, HBoV can cause life-threatening infections and prolonged shedding in immunocompromised patients, and for immunocompetent children a median shedding time of 50 days has been reported ([@B92]; [@B5]; [@B89]; [@B35]; [@B103]). This long shedding period might lead to more severe disease in immunocompromised children ([@B136]). Importantly, HBoV does not exhibit seasonality and thus remains a threat throughout the year.

Human Coronavirus
-----------------

Human coronavirus belongs to the *coronaviridae* that are endemic in humans. Annually HCoV are responsible for 15--30% of URI with pharyngitis and rhinitis in immunocompetent hosts. Historically, two common HCoV were known: HCoV-229E and HCoV-OC43. However, the emergence of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) along with two further HCoV (HCoV-HKU1 and HCoV-NL63) has expanded the family ([@B169]; [@B181]). In contrast to the low incidence of bronchitis or pneumonia in healthy children, severe clinical features have been described in immunocompromised patients. Both the presence of a respiratory co-pathogen (RSV) and host factors like young age \< 5 years and an immunocompromised status were reported to contribute to LRI. However, it should be noted that only 10 children with HCT were included ([@B119], [@B120]). In separate studies, HCoV have been associated with increased mortality and prolonged shedding in the HCT setting ([@B110]; [@B131]). Risk factors for prolonged shedding (at least 21 days) in the upper respiratory tract were determined in a cohort of 44 patients and included high viral load, myeloablative conditioning, and prior high-dose steroid use ([@B118]). Of 44 patients, 31 samples were analyzed shown to contain evidence of HCoV-OC43 (35%), HCoV-NL63 (32%), HCoV-HKU1 (19%), and HCoV-229E (13%) infection. Analysis for duration of shedding showed that none of the strains appeared to cause longer shedding compared with others. In addition, genomic approaches investigated whether viral genome evolution could identify genetic changes associated with prolonged shedding. Identification of such changes could aid the development of new antiviral agents. Single nucleotide polymorphisms could not be identified until day thirty after the onset of viral shedding. This finding might not be surprising given the protracted evolution rate of HCoV. However, overt viral genome changes might occur at a later time point, and changes in genome composition might result in a modification of the treatment strategy ([@B118]). In another study, HCoV were examined in BAL ([@B119]). The median time to HCoV LRI occurrence was 302 days after HCT. Among 23 BAL samples analyzed, 48% were HCoV-OC43, HCoV-NL63 was detected in 22%, HCoV-229E in 17% and HCoV-HKU1 in 13%. Although somewhat limited because of sample size, these data show a similar frequency and order of detected viral strains compared to those detected from nasal samples with the exception of HCoV-HKU1 which was predominant in nasal samples ([@B118]). The detection of RSVs did not change clinical outcome.

Influenza Virus
---------------

Influenza virus, an *orthomyxoviridae* member, exhibits high genomic variability due to an absence of proofreading activity in its RNA -- a process that contributes to antigenic drift. As some IFV strains are more virulent than others, the strain of IFV impacts on severity, depending on circulating strains, and this can be impacted upon by the composition of the vaccine and also the uptake of vaccine in the population. Individuals with a compromised immune system such as the elderly and HCT recipients are at increased risk of complications and death, and outbreaks in HCT units have been reported ([@B93]; [@B160]). In HCT recipients, fever maybe absent in about 19% of cases as might classical symptoms such as sore throat, nasal congestion and discharge, cough, chills and myalgia ([@B100]). As with other respiratory viruses, IFV shedding in HCT patients has been reported to be prolonged with a median of 12 days; lymphopenia correlated with the duration of shedding, and steroid use \> 1 mg/kg increased IFV secretion ([@B81]; [@B19]; [@B47]). Infants may present with sepsis-like symptoms and pneumonia. Complications in adults include pneumonia, myocarditis, encephalitis and Guillain-Barré syndrome. As with PIV infections (see below), bacterial and fungal co-infections with IFV are known ([@B117]; [@B47]). Disease progression to LRI takes place in up to 35% and mortality ranges between 15 and 28% in patients diagnosed with pneumonia. Therefore, early treatment within 2 days of presenting with symptoms has been favored ([@B178]; [@B117]; [@B24]; [@B87]). While risk factors have been validated for RSV and PIV, equivalent quality indicators are limited for IFV. Potential risk factors that might result in LRI are lymphopenia and neutropenia as well as increased age (\>65 years) while steroid use is unclear ([@B101]; [@B24]; [@B30]). IFV genome detection in blood was associated with hypoxemia, respiratory failure, and overall mortality ([@B30]). [@B87] applied an ISI that had been developed for RSV to identify patients with IFV infection who might run at risk to develop progression to LRI ([@B149]). According to variables such as age, neutrophil and lymphocyte counts, conditioning regimen, steroid use and time from transplantation, HCT recipients were grouped into low, moderate, and high risk immunodeficiency categories. A high risk score was applied if the score was between 7 and 12 and was likely to include ANC \< 500/mm^3^ (score 3) and/or ALC \< 200/mm^3^ (3), age ≥ 40 years (2), myeloablative regimen (1), GvHD (1), steroid use within the last 30 days (1) and recent (within the last 30 days) or pre-engraftment allogeneic HCT (1). Patients with a high risk score had a significantly higher probability of developing LRI compared to the low risk group ([@B87]).

Human Metapneumovirus
---------------------

Human metapneumovirus, formerly a member of the *paramyxoviridae* now belonging to the *pneumoviridae*, was identified in 2001 as an agent capable of causing respiratory disease in children ([@B168]). In immunocompetent individuals, HMPV causes symptomatic URI and LRI predominantly in children or adults above 65 years of age ([@B16]). No specific symptoms that distinguish HMPV from other viral respiratory infections exist. It has been reported that disease is more severe in case of a RSV co-infection but these data are considered controversial. In immunocompetent children, one study revealed that HMPV with RSV co-infection increased bronchiolitis ([@B142]), however, this could not be substantiated in other studies that investigated single infections and co-infections for HMPV and RSV ([@B111]; [@B183]). For both HMPV and RSV, A and B types occur that can be distinguished by different primer sets in PCR ([@B133]). Immunocompromised children are at higher risk of developing LRI with higher risk of requiring intensive care treatment with increased mortality ([@B31]). In a study of 21 HCT recipients, HPMV infection was documented in the majority of patients but did not cause any symptoms or disease ([@B36]). However, in a study that included 251 episodes of URI and LRI, 16 of the 22 episodes in which HPMV was detected occurred in HCT recipients, resulting in an infection rate of approximately 6% of all HCT patients ([@B179]). Another study revealed HPMV in BAL samples from 5 of 163 patients who became symptomatic within a month after engraftment, and fatality reached up to 80% if BAL was positive for HMPV ([@B49]). Progression to LRI has been reported to take place between 21 and 40% ([@B131]). For HMPV, risk factors for mortality include length between HCT and infection; neutropenia, lymphopenia, low monocyte count at diagnosis, and a steroid dose before diagnosis of ≥1 mg/kg ([@B145]). In the latter study, the presence of co-pathogens contributed to higher risk. Glucocorticoid application and lymphopenia have been identified as risk factors that contribute to progression from URI to LRI ([@B145]). In a systematic review, HMPV progressed to LRI in 34% of cases and the mortality rate increased from 6 to 27% when LRI was present but no HMPV-associated risk factors for increased mortality could be identified ([@B152]).

Parainfluenza Virus
-------------------

Parainfluenza virus is a member of the *paramyxoviridae* that circulates throughout the year. PIV causes LRI in approximately 20% of healthy children ([@B12]) and is also responsible for life-threatening LRI in HCT recipients ([@B158]; [@B151]). Four PIV serotypes are known. PIV serotype 3 (PIV-3) is the most frequent occurring serotype and has been responsible for infections after HCT ([@B32]; [@B116]; [@B106]; [@B70]). In one study comprising 3577 patients with PIV infection, 6.4% had an infection with PIV-3, and 24% of these patients developed pneumonia ([@B114]). Another study reported PIV infections in up to 18% of cases during the first 3 months post HCT ([@B124]). In 20--40% of patients who experience URI, infection progresses to LRI with a median time of 78 days. Virus-associated mortality is around 10% after PIV infection but increases to 27% if infection progresses to LRI ([@B114]; [@B158]; [@B25]; [@B167]; [@B147]; [@B151]). PIV risk factors for progression to LRI are lymphopenia, steroid use and co-infections with other respiratory agents, however, myeloablation and infections in the early post-transplant period were variables with unclear association ([@B148]; [@B151]). Pulmonary co-pathogens, e.g., *Aspergillus fumigatus*, are often present in patients with pneumonia and highly contribute to mortality ([@B114]; [@B167]).

Respiratory Syncytial Virus
---------------------------

Respiratory syncytial virus, now also belonging to the *pneumoviridae*, is a frequent pathogen in infants and children that causes URI with rhinitis and laryngitis but also bronchitis and pneumonia if progression to LRI occurs. In HCT recipients, RSV infections occur up to 30% ([@B104]; [@B82]; [@B10]; [@B153]; [@B173]). In approximately half of the HCT recipients with URI caused by RSV, infection will progress and result in pneumonia that is associated with average mortality rates around 30% without effective treatment ([@B115]; [@B15]; [@B82]; [@B153]; [@B144]; [@B173]). Risk factors for progression to LRI include advanced age, lymphopenia, myeloablative regimen, steroid use, GvHD and pre-engraftment infection and occur at a mean of 38% ([@B115]; [@B104]; [@B82]; [@B153]; [@B67]). Further, smoking history, conditioning with high-dose total body irradiation with 1200--1575 cGy and specifically an absolute lymphocyte count ≤ 100/mm^3^ at URI onset were significantly associated with progression to LRI. In contrast, lung function, steroid use, lymphocyte engraftment dynamics, RSV subtypes and subtype-specific neutralizing antibody levels were not associated with progression, revealing transplant-related rather than viral factors which might put a focus on the characterization of RSV-specific T cells ([@B84]). In addition, absolute lymphocyte counts of \> 1000/mm^3^ at URI onset were protective and no advance to LRI was observed. Another study that examined risk factors for RSV RNA detection in serum or plasma identified mechanical ventilation, neutropenia, monocytopenia as well as thrombocytopenia as associated factors, however, lymphopenia and steroid use did not increase the risk of RSV RNA plasma detection ([@B173]). For that study, a median time of 52 days to LRI onset was described.

As described for IFV, an ISI had been originally proposed to stratify RSV-infected patients into groups based on their risk of progression from URI to LRI and to evaluate RSV-related mortality ([@B149]). This stratification should help to identify patients who might profit from antiviral therapy such as aerosolized ribavirin. This index is based on age, absolute neutrophil and lymphocyte counts, acute or chronic GvHD, myeloablative conditioning, corticosteroid use and time of infection. However, validation of this index needs to be performed in multicenter studies.

Rhinovirus
----------

Rhinovirus, a member of the *picornaviridae*, comprises more than 100 serotypes and are divided into the three species A, B and C. There is no seasonal preference for RhV, however, more infections might occur during spring and autumn. RhV are the most frequently detected community-associated respiratory viruses that cause cough, a runny nose but also bronchitis or pneumonia in HCT recipients ([@B75]; [@B110]). Symptomatic RhV infections occur in 10--30% of HCT recipients and initial high viral loads are associated with prolonged shedding ([@B122]; [@B110]; [@B121]). A recent study showed that median shedding time among patients with RhV infection was 9.5 days, and 18/38 (47%) of HCT recipients had prolonged RhV shedding (at least 21 days; range, 2--89 days) that was similar for all three species but the majority of patients (69%) shed RhV species A. Risk factors for prolonged RhV shedding pointed to a high initial viral load as defined by a Ct value below the median (30.3) ([@B121]). Infection control measures should consider these long infection periods. Progression to LRI is increasingly being detected and fatal outcomes due to RhV infections have been described ([@B62]; [@B76]; [@B121]).

From Colonization to Symptomatic Infection After HCT
====================================================

Patients who reveal respiratory tract infection symptoms before HCT should be tested for respiratory pathogens by multiplex PCR. Campbell et al. analyzed data from 458 adult and pediatric patients and identified 25% of patients to be positive for at least one respiratory virus pre-transplant. Symptomatic patients had lower survival 100 days after HCT compared with patients with negative test results and increased overall mortality. Since this risk was increased even if only RhV was detected, the authors proposed to consider deferral of HCT in symptomatic patients with any respiratory virus positive, not just only in case of RSV, IFV, PIV, or HMPV detection. Asymptomatic patients with a virus detected did not exhibit higher mortality and HCT might proceed as planned; however, it is unclear if these patients actually shed replicating virus or if only viral nucleic acid is being detected. There was no higher incidence of bronchoscopy in the symptomatic versus the asymptomatic group. Any decision to delay transplant has to consider HCT factors such as underlying disease, the conditioning regimen associated with it and donor logistics ([@B21]). In a follow-up study that focused on pediatric HCT recipients, [@B85] detected respiratory viruses pre-transplant in 81 of 218 patients. RhV were detected in 24% of cases, followed by a group of viruses consisting of AdV, RSV, HMPV PFV, and PIV (11%). Pre-transplant detection was associated with increased hospitalization during the first 100 days, and HCoV was only detected pre-transplant in 2% of cases.

Since the conditioning regimen might have an impact on the incidence of respiratory virus infections pre-transplant, patients with myeloablative and non-myeloablative conditioning were compared. The incidences for respiratory virus infections were similar among both groups. However, in contrast to patients receiving non-myeloablative conditioning, LRI are significantly increased during the first 100 days post HCT when myeloablative regimen was given ([@B137]).

Immediately after HCT in the neutropenic phase, patients frequently develop febrile episodes and are especially prone to bacterial infections. Therefore, they are often treated with antibiotics to protect them from life-threatening bacterial infections. This treatment alters microbiota composition and has an impact on immune responses ([@B74]; [@B3]; [@B44]). An immunodulatory compound associated with microbiota is butyrate, a short chain fatty acid that is important in maintaining gut microbiome equilibrium as well as in controlling immune responses in organs such as the lung ([@B43]; [@B23]). In a recent study, [@B63] investigated the influence of butyrate on microbiota composition and its influence on respiratory viral infections and the associated risk to develop LRI in HCT recipients. Patients who received antibiotic treatment resulting in altered microbiota colonization and diminished butyrate-producing bacteria had a higher risk of developing LRI indicating that the presence of butyrate-producing bacteria appears to be protective ([@B63]). A recent analysis from the Seattle group has shown that antibiotic exposure before the onset of viral respiratory infection increases the risk of progression from URI to LRI in case of HMPV, PIV and RSV infection ([@B120]). However, a certain class of antibiotics that poses a particular risk could not be identified.

Another recent study described significant lower overall survival for patients with respiratory virus infection accompanied by bacterial co-infection that contributed to increased mortality ([@B127]). Risk factors for developing bacterial co-infection following a respiratory viral infection were steroid use ≥ 1mg/kg/d and CMV DNAemia requiring antiviral therapy. Mortality-associated risk factors such as lymphopenia \< 0.5 × 109/ml, CMV DNAemia requiring antiviral therapy at the time of viral LRI diagnosis and oxygen support at the time of BAL were used to establish a risk score in order to stratify patients to help predict mortality, no matter if a co-infection was present or not. This new risk score was compared to other scores including the ISI described above, however, the application of ISI criteria did not prove useful to predict mortality in this cohort. Currently, ISI does not include co-infections as a variable, and future studies are needed to validate and compare different risk scores ([@B127]). The profound lymphopenia after HCT has been described as a risk factor in the study above and multiple other studies, and it has recently been suggested that CD8 T cells may protect against a secondary infection ([@B140]).

Diagnostic Workup
=================

The fourth European Conference on Infections in Leukemia (ECIL-4) developed guidelines for diagnosis and treatment on several respiratory viruses ([@B67]). HCT candidates and recipients with URI or LRI should be tested for respiratory viruses to guide infection management and possible deferral of transplantation. Specimens should be taken from the site of infection; for URI, pooled swabs should be analyzed and for LRI, a tracheal aspirate or ideally a BAL should be performed. However, patient circumstances often do not permit invasive procedures. These guidelines favored a first-line screening for IFV A and B, RSV, and PIV, however, with more advanced multiplex PCR assays becoming available, all agents might be examined at once ([@B174]).

Over the past years, more respiratory infections in HCT recipients have been reported due to the development and use of new diagnostic methods. Routine molecular diagnostics of respiratory viruses nowadays includes multiplex PCR approaches that have improved detection of respiratory agents in HCT recipients ([@B95]; [@B135]). Multiplex assays covering the relevant respiratory viral agents are preferred over laborious and time-consuming viral culture and direct fluorescence antibody assays because of its sensitivity, specificity and rapid turnaround time. In addition, viral nucleic acid quantification is important because determination of a viral load might indicate prolonged viral shedding in case of RhV ([@B121]). However, this does not provide information about active replication and viral culture techniques are not well established, e.g., for HCoV.

A problem with virus detection is a lack of standardization among assays since different primers, probes and techniques are used ([@B72]). Nasal respiratory swabs are routinely performed pre-transplant and should be collected in case of suspected respiratory infection. A large prospective study associated respiratory virus detection before transplantation with prolonged hospitalization and decreased survival at day 100 ([@B21]). RhV detection after a routine pre-transplant screening can result in fatal infection, even if the patient is asymptomatic and presents with regular findings on chest CT ([@B110]; [@B21]; [@B174]). If any respiratory virus is identified by multiplex PCR pre-transplant, HCT should be postponed ([@B20]; [@B123]; [@B67]). However, as occurs in leukemia relapse cases, the time window from remission to HCT can be narrow, thus making a decision difficult. Irrespective of URI or LRI, transplant should be delayed if possible, probably even in cases where data are scarce as is the case in HCoV and HBoV infections. While episodes of both URI and LRI have shown a higher mortality risk in symptomatic adults in contrast to asymptomatic patients ([@B1]), transplant delay should be recommended in symptomatic adults. However, in pediatric patients who tend to shed virus more frequently than adults and acquire viruses more frequently, transplant delay should be considered on a case by case basis in asymptomatic patients.

In aiding to determine progression from URI to LRI, radiologic signs are considered an important component although inter-observer variability is high and radiologic signs are sometimes difficult to interpret ([@B46]; [@B56]). It is important to perform useful radiologic diagnostics in symptomatic patients with suspected LRI. Chest x-rays are generally not recommended because lack of sensitivity but CT should be performed to evaluate LRI. In children, chest x-rays do not provide specific information in case of HMPV infection where common findings include hyperinflation, atelectasis and perihilar opacities ([@B66]).

In an attempt to try and provide a standardized framework a scoring tool named the RSI has been established to quantify severity of radiologic findings and correlate them with outcome in PIV LRI. Infiltrate expansion, when longitudinally assessed by RSI, was predictive of mortality in patients with PIV-associated disease and discrepant results were obtained when CT and chest X-ray findings were compared. Early signs suggest that the RSI appears to be a useful tool to predict mortality but needs to be validated in future studies ([@B155]).

Computed tomography findings associated with LRI include bronchial wall thickening and diffuse or patch-like ground glass opacities as a sign of interstitial infiltrates ([@B57]; [@B65]). However, radiologic approaches often do not show clear signs of infection in symptomatic patients. Additionally, the occurrence of simultaneous infections means correlating a specific virus with CT findings is difficult. To address this, a retrospective study by [@B83] examined CT scans from LRI patients with BAL specimens and single infections of either RSV, IFV or PIV in order to identify virus-characteristic CT lesions. Patch consolidations of at least one centimeter or more than one segmental level were only observed in PIV infections. Ground-glass opacities were identified in all CT scans when IFV was detected and were less frequently seen with PIV (detected in 71% of cases) and RSV (67%). Bronchial wall thickening was prominent with IFV and RSV in about two thirds of CT scans analyzed whereas it was seen in only one third in PIV infections. Anatomically, RSV infection was localized in the upper and middle lobes (44%), PIV preferentially in the lower lobes (69%) and IFV infection resulted in a diffuse pattern ([@B83]). However, due to the retrospective nature of the study by Kim et al., no distinction between early and late infection stage CT findings could be made which might have revealed different patterns. Other studies similarly identified ground-glass opacities for IFV infections ([@B57]; [@B77]) and bronchial wall thickening combined with nodules and tree-in-bud in RSV infections ([@B105]). Another small study also detected bronchial wall thickening in patients with confirmed RSV infections but also ground-glass opacities, and these findings were equally seen in hMPV infections where lesions appeared to be more asymmetrical ([@B161]). Although CT findings appear to be non-specific, they might help to differentiate between pathogens causing LRI if a thorough diagnostic workup including multiplex PCR with representative specimens is employed to largely rule out simultaneous infections.

Treatment
=========

Infection Control
-----------------

### Virus Spread Prophylaxis

Infection control measures are of high importance and should be in place in case of suspected or confirmed respiratory virus infection ([@B14]). Since these viruses are transmitted by close contact with infected individuals or contaminated material, hand hygiene is of utmost importance since nosocomial infections have occurred that must be avoided ([@B71]). The use of universal surgical mask might also be useful to prevent respiratory viral infections after HCT ([@B159]). Patients with documented respiratory virus infection should be isolated with restricted contact and strict protection measures should be applied (gloves, gowning, masks, eye protection) to visitors and healthcare workers ([@B67]). Since HCT recipients might shed these viruses for a long time because of their impaired immunity, precautions should be taken if a patient is discharged. For example, a patient should be escorted through the outpatient clinic to avoid direct contact with and spread to other patients, and prolonged isolation might be necessary ([@B163]; [@B67]). This might be especially important for RhV in case high viral loads are detected since shedding time in these patients exceeds 21 days ([@B121]). However, PIV-3 and HMPV infections might go unrecognized in immunocompetent persons, thus making it difficult to prevent infection ([@B115]; [@B37]; [@B152]; [@B13]).

### Reduction of Immunosuppression

Each time a respiratory tract infection is proven after HCT, a reduction of immunosuppressive treatment should be the response. A steroid dose greater than 1 or 2 mg/kg/day has been proven to be an independent risk factor for overall mortality in LRI with RhV ([@B146]), RSV ([@B151]), HMPV, and PIV ([@B174]). However, no correlation between progression or mortality and steroid dose was found for IFV ([@B174]).

Specific Drugs
--------------

### Adenovirus

Adenovirus pneumonia is usually observed in AdV disseminated disease. Preemptive treatment is recommended as soon as viremia is higher or equal to 1000 copies/ml coupled with lymphocyte counts below 300/mm^3^ and CD4 T lymphocyte counts below 25/mm^3^ ([@B68]). This is particularly important in high risk patients and those who received cord blood graft or are under steroid treatment ([@B97]). High AdV levels in stool have also been associated with gastrointestinal AdV disease ([@B51]) -- an observation that underpins a current clinical trial addressing the usefulness of a preemptive treatment based on stool AdV detection^[2](#fn02){ref-type="fn"}^. So far, no recommendation has been made for AdV detection in upper airways. Specific treatment of AdV pneumonia should be given as early as possible after diagnosis ([@B113]; [@B97]).

Several studies have reported successful Cidofovir treatment of AdV infections in immunocompromised hosts after HCT, combined with withdrawal of immunosuppression (e.g., at 5 mg/kg once every week for 2 weeks, followed by a maintenance dose of 5 mg/kg once every fortnight, or three times weekly at 1 mg/kg) ([@B97]; Wy [@B182]). Cidofovir inhibits incorporation of deoxycytidine triphosphate into viral DNA by the viral DNA polymerase, leading to viral DNA chain termination. Probenecid co-prescription is useful to prevent or diminish cidofovir nephrotoxicity due to its accumulation in renal tubules. Cidofovir is the current standard of care treatment for AdV infections and diseases. However, cidofovir does not clear the virus in the absence of T cell immune reconstitution ([@B68]).

Another novel compound is CMX001 (hexadecyloxypropyl cidofovir, brincidofovir, Chimerix), an orally bioavailable lipid conjugate of cidofovir with good oral bioavailability which achieves higher intracellular levels of active drug compared with cidofovir. Brincidofovir lacks nephrotoxicity making it an attractive alternative. In phase I and phase II trials as well as in retrospective studies, brincidofovir has been shown to be highly efficacious in controlling and clearing adenoviraemia ([@B61]; [@B68]; [@B130]; [@B9]). Gastrointestinal toxicity is the major side effect observed and might be associated with epithelial apoptosis and crypt injury, as might be observed with GvHD ([@B38]).

Further, a small compound inhibitor named HBX has been reported to be effective against AdV infections. A cellular component important for AdV replication is ubiquitin-specific protease 7 (USP-7), a deubiquitinating enzyme of the ubiquitin proteasome pathway. USP-7 interacts with E1B-55K, a regulator of AdV replication. Since USP-7 promotes AdV replication, it represents a potential drug target because blocking its activity could aid in the treatment of AdV infections ([@B27]). HBX and a derivative were generated that were able to block AdV (C5 type) replication. With the exception of AdV types A12 and A31, HBX effectively blocked *in vitro* replication of all AdV tested, making it a promising new antiviral candidate ([@B91]).

For AdV, there is no proven role for ganciclovir, foscarnet or immunoglobulin therapy in immunocompromised patients. Importantly, donor lymphocyte infusions and more recently specific anti AdV cytototoxic T cells should be considered in case of AdV disease after HCT (see below). There is anecdotal evidence of successful treatment of AdV with ribavirin ([@B139]) but most studies have not been supportive; ([@B94]) and conclude that cidofovir combined with immunotherapy is more efficient and should be preferred as the first treatment option. Of note, Ribavirin is active *in vitro* on species C isolates ([@B112]).

### HBoV, HCoV, and RhV

There is currently no recommendation of specific antiviral therapy due to the lack of effective agents against these viruses and the lack of clinical trials ([@B67]). Several agents against RhV have been described in the context of immunosuppression: Oral or intranasal pleconaril, a capsid binder, was effective in 2 randomized trials to mildly reduce the duration and severity of colds in immunocompetent adults but its development was halted after FDA rejection partly due to concerns regarding virus resistance ([@B143]). Vapendavir is another capsid binder under development^[3](#fn03){ref-type="fn"}^ for the treatment of RhV infections of asthmatic adults ([@B174]).

### Influenza Virus

To avoid transmission of IFV, vaccination of family members, household contacts and HCT recipients is recommended. However, HCT recipients might not mount an adequate immune response if vaccination takes place during immunosuppression. Available antivirals for IFV infections include the M2 ion channel inhibitors such as amantadine that exclusively act on IFV-A. However, neuraminidase inhibitors (NAI) are preferred for prophylaxis and treatment of IFV infections since resistance to M2 inhibitors is frequent ([@B50]; [@B55]; [@B171]). Post exposure prophylaxis with oral oseltamivir, 75 mg bid for 10 days for adults and children whose weight is above 40 kg, is the current treatment of choice. Oral oseltamivir, inhaled zanamivir and IV peramivir are NAIs that were shown to be effective in HCT recipients ([@B172]; [@B163]; [@B22]; [@B29]; [@B47]). Treatment within 48 h after the occurrence of symptoms will result in better outcome ([@B101]; [@B117]; [@B163]; [@B29]; [@B47]); Although treatment should be initiated as early as possible, protracted and also prolonged treatment have been shown to have favorable effects. The duration of therapy should extend the treatment period recommended for immunocompetent hosts to circumvent reoccurrence and might last for 10 days in HCT recipients. Also, longer therapy in case of unsuccessful clearance might be necessary ([@B47]).

The most commonly described mutation resulting in oseltamivir and peramivir resistance is conferred by the H275Y mutation in influenza A H1N1 that can be treated with inhaled zanamivir ([@B109]; [@B47]). In Europe during the 2007--2008 winter season, high resistance rates up to 68% of IFV-A (H1N1) to oseltamivir have been reported ([@B108]). New agents with potential efficacy against oseltamivir-resistant viruses are being tested like inhaled laninamivir which is available in Japan, JNJ-63623872, a non-nucleoside inhibitor of the RNA polymerase protein PB2, Nitazoxanide, an antiparasitic agent with activity against IFV, and antibodies (MEDI8852, VIS410) ([@B154]).

### Parainfluenza Virus

In a retrospective analysis of 200 patients including 120 HCT recipients, one-third of patients with PIV infection had lower respiratory tract disease and independent risk factors of progression were neutropenia, APACHE II score ≥ 15, and respiratory co-infections within a month of PIV infection. In this study, treatment with aerosolized ribavirin and/or IVIG did not prevent progression to pneumonia and did not affect duration of illness or survival ([@B25]). A meta-analysis performed in 2016 reinforced this evidence of inefficiency of ribavirin for PIV: indeed, PI-LRI progression was not significantly different in HCT recipients who were treated with ribavirin at URI stage, and PIV-associated mortality rate was slightly higher in patients treated with ribavirin-based therapy at LRI stage than in those who were not treated ([@B151]). A recombinant sialidase fusion protein inhibitor named DAS181 has been used to treat severe PIV infections after HCT ([@B175]; [@B41]; [@B134]). DAS181 cleaves the Neu5Ac α(2,3)-Gal and Neu5Ac α(2,6)-Gal sialic acid linkages on the surface of respiratory cells that are used by IFV and PIV for attachment and entry, thereby inhibiting the latter. The largest cohort included 16 patients after HCT, 14 of who received DAS181 for PIV-associated pneumonia but unfortunately lacked a control group ([@B134]). Thirteen out of 16 patients responded to treatment, and the three patients who did not respond had a viral, bacterial, or fungal co-infection, respectively. The drug was well tolerated. PIV loads were recorded in 7 of 16 patients using nasopharyngeal swabs. A \> 1 log decrease in PIV load was seen in 5 of 7 patients accompanied by a partial or complete clinical response. High-dose IVIG had no effect on mortality after PIV LRI in a retrospective analysis of 544 patients with PIV infection after HCT ([@B147]). Therefore, no specific treatment for PIV infection is currently strongly recommended. However, current ECIL-4 guidelines suggest treatment with aerosolized ribavirin or off-label use with systemic ribavirin. For infections other than PIV and RSV, ribavirin use is not recommended ([@B67]).

### Human Metapneumovirus

In a study among 105 patients with URI from the Fred Hutchinson Cancer Center ([@B145]), the probability of progression to LRI within 40 days was 16%, and approximately 75% of the patients with URI who progressed to LRI did so within 2 weeks after URI. Even if several small reports support the use of ribavirin with or without IVIG for HMPV infection, a larger study showed no protective effect of ribavirin to reduce HMPV progression and mortality ([@B133]). To date, antiviral therapy is not recommended to cure or to prevent infection progression even in patients at higher risk of HMPV progression. No licensed therapeutics or vaccines exist ([@B177]). Therefore, treatment for HMPV remains so far non-specific and mainly supportive. MAb 338, a monoclonal antibody against a fusion protein of HMPV, demonstrated interesting results in hamster and mice models, and further investigation in clinical trials is warranted ([@B165]; [@B64]).

### Respiratory Syncytial Virus

In 2013, international guidelines recommended aerosolized or systemic (oral or IV) ribavirin with IVIG in patients with RSV URI undergoing allogeneic HCT, allogeneic HCT recipients with risk factors for progression to LRI, and allogeneic HCT patients with LRI ([@B67]). However, the additional benefit of IVIG remains controversial. In a retrospective study that reviewed RSV URI or LRI infections in 280 HCT recipients, a combined IVIG and ribavirin treatment was beneficial ([@B150]). Further, given significant exponential cost increases in aerosolized ribavirin between 2013 and 2015 and lack of evidence that aerosolized ribavirin is more efficient, early oral ribavirin treatment is currently more frequently considered ([@B174]) and is well tolerated (e.g., 15 mg/kg/day in three divided doses for 10 days) ([@B60]). A clinical trial comparing RSV treatment with oral *versus* inhaled ribavirin is ongoing^[4](#fn04){ref-type="fn"}^. However, in France, aerosolized ribavirin is currently not available.

Lymphopenia is a specific risk factor that has been associated with progression to LRTI in several studies. Other risk factors such as total body irradiation, smoking history, stem cell source other than peripheral blood stem cells and oxygen requirement might be considered ([@B144]; [@B173]). A lower virulence of RSV-B compared to RSV-A has been reported ([@B80]). As stated above, the ISI might be helpful to identify patients who would benefit from antiviral therapy ([@B151]).

Data from studies with the RSV-specific monoclonal antibody palivizumab have shown controversial efficacy, apart from the fact that it is very costly in adults. In larger studies of HCT recipients with RSV LRI, adjunctive palivizumab did not lead to outcome improvement ([@B144]; [@B173]). Therefore, RSV-specific monoclonal antibody is not recommended as a treatment option and might be only discussed for very young (age \< 2 years) allogeneic HCT recipients with LRI or at high risk for progression to RSV LRI (e.g., palivizumab 15 mg/kg body weight) ([@B67]).

Moreover, several agents are under development against RSV infections ([@B154]). Firstly, there are fusion inhibitors like GS-5806 which reduced the viral load and the severity of clinical disease in a study of healthy adults ([@B40]), MDT-637^[5](#fn05){ref-type="fn"}^ and ALX-0171. Secondly, agents targeting the RSV polymerase exist: AL-8176 which had an interesting antiviral activity compared to placebo in 62 healthy adults inoculated with RSV ([@B39]) and favipiravir which is currently being tested in phase III clinical trials in the United States, Europe, and Latin America. Thirdly, substances targeting the viral nucleocapsid protein have been investigated. A small interfering RNA called ALN RSV01 inhibiting the synthesis of the RSV nucleocapsid protein has demonstrated a benefit in phase I to IIb clinical trials by decreasing the infection rate, reducing symptoms and the incidence of bronchiolitis obliterans. Another drug, RSV-604, targets the N terminal portion of the nucleocapsid protein. It was tested on HCT recipients, however, no data have been published ([@B156]). Finally, polyclonal high-titer anti RSV antibodies might be an option (RI-001)^[6](#fn06){ref-type="fn"}^.

Current strategies recommended for the treatment of respiratory viral disease after HCT, and molecules that are under investigation, are summarized in Table [1](#T1){ref-type="table"}.

###### 

Treatment algorithm of respiratory viral infections after HCT.

  \(1\) Steroid dose withdrawal (if applicable) below 1 mg/kg/day (except for IFV)                                                                                                                                                                                                                                                   
  ----------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------- ------------------------ --------- ---------------------------------- ------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------------
  First-line treatment recommendations                                                                        Oral ribavirin 30 mg/kg/day in 3 divided doses, 10 days                                                                                       IV Cidofovir 5 mg/kg once a week (2w) and 5 mg/kg once every fortnight   Oral oseltamivir 75 mg bid (30 mg bid 10--15 kg, 45 mg bid 16--23 kg,. 60mg bid 24-40 kg) for 10 days
  Alternative treatment                                                                                       +IVIG IV ribavirin Inhaled ribavirin Palivizumab (young children)                                                                             Oral brincidofovir (2mg/kg twice a week\] Anti-ADV CTL                   NAI: inhaled zanamivir IV peramivir Zanamivir (if resistance) M2 ion channel inhibitor: amantadine (IV-A)
  Drugs/immunotherapy in development                                                                          GS-5806 MDT-637 ALX-0171 Favipiravir RSV-604 AL-8176 ALN-RSV01 RI-001   DAS 181 Anti PIV-3 CTL   MAb 338   Oral/nasal pleconaril vapendavir   HBX                                                                      Inhaled laninamivir Nitazoxanide MEDI8852 VIS410
  ↓                                                                                                                                                                                                                                                                                                                                  
  **(3) Virus spread prophylaxis: hand hygiene, surgical mask, vaccination of family, prolonged isolation**                                                                                                                                                                                                                          

AdV, adenovirus; HMPV, human metapneumovirus; RhV, rhinovirus; IFV, influenza virus ; IVIG, intravenous polyvalent immunoglobulins ; LRI, lower respiratory tract infection; NAI, neuraminidase inhibitor; PIV, parainfluenza virus; RSV, respiratory syncytial virus.

Immunotherapy After HCT
-----------------------

Before the era of specific antiviral manufactured T cells, donor lymphocyte infusions (DLI) were used and recommended in case of disseminated AdV infections after HCT ([@B18]; [@B162]). The high incidence of GvHD after DLIs limits its use in patients with previous history of GvHD. Anecdotal use of DLI has been reported for threatening RSV LRI ([@B86]).

There are currently three strategies to manufacture viral specific T cells (VST) for clinical use: The first one is direct selection of antiviral T cells, either by multimers specific for a virus-derived peptide in the setting of class I HLA molecule, or by column selection of IFN-γ expressing T cells (with immunomagnetic beads) after viral antigen stimulation ([@B54]; [@B125]; [@B73]). The second one is *ex vivo* expansion of T cells co-cultured with antigen presenting cells pulsed, infected or transfected with viral peptide/protein/viral lysate or plasmid ([@B126]; [@B59], [@B58]). The third one is genetic modification of T cells which incorporate high affinity VSTs receptor or chimeric antigen receptor genes ([@B141]; [@B33]; [@B17]).

So far, in the setting of community acquired viral respiratory infections, adoptive immune therapy has been developed and investigated in clinical trials only for AdV infections. This strategy is promising as it has been reported to offer a way to cure severe adenoviral infections in case of resistance to antiviral drugs. Adenoviral clearance has been obtained after infusions of AdV-VST generated by interferon \[IFN-γ-based immunomagnetic isolation (and further *in vivo* expansion) from initial donor or third party donor\] in 10 of 11 hematopoietic stem cells transplanted patients in a French phase I/II trial ([@B129]). Similar results have been published earlier ([@B52]) from 30 patients who received AdV-VST for AdV disease or viremia. 14 of 23 evaluable patients had *in vivo* expansion of Th1-VST (median time 24 days); and 21 patients responded to VST infusions and AdV clearance occurred in 14. Of note, AdV-VST infusions were not associated with acute toxicities or significant onset of GvHD. The main disadvantage of this technique is that high doses of immunosuppressive drugs and especially steroids should be avoided before infusions as this drug hampers *in vivo* expansion of specific T cells.

Currently, multiviral (including AdV) T cell manufacturing and banking from a third-party donor is a promising strategy as it might offer an immediate way to prevent AdV infections after HCT or to cure 71% of AdV infected patients after HCT ([@B164]). *Ex vivo* expanded cytotoxic T cells against PIV-3 antigens should be further tested in clinical trials ([@B107]; [@B4]).

Outcomes and Later Monitoring
-----------------------------

### Overall Mortality and Risk Factors

The outcome in patients who experience progression to LRI is worse compared to patients with URI regardless of the virus involved ([@B26]). In a French cohort of 131 adult patients infected with viral respiratory infections, 16 (12%) died within 3 months. Among these, eight patients (6%) died of viral pneumonia along with bacterial and/or fungal pneumonia. Interestingly, the virus group and the time from HCT had no impact on mortality. Two factors were independently associated with increased overall mortality: steroid dose over 1 mg/kg body weight and a lymphocyte count lower than 0.5 g/L ([@B180]). The fact that LRI associated death risk does not depend on the virus type is supported by [@B146] who reported an overall mortality probability at day 90 as high as 41% in patients after HCT who developed RhV LRI, a rate that was comparable to RSV, PIV and IFV LRI in an adjusted model. Among children, in a cohort of 58 patients, 3 (5%) died of respiratory failure ([@B28]). LRI in the absence of URI and adenoviral infection has been described to be associated with a poorer outcome in another cohort of 166 patients with specific overall mortality of 7% ([@B102]).

### Pulmonary Outcomes After Viral Infections

Bronchiolitis obliterans syndrome and obstructive airflow decline have been associated with PIV and RSV infections within the first 3 months after allogeneic HCT which persisted at 1 year after transplant ([@B170]). Further, the occurrence of a LRI within 100 days post-transplant was an independent predictive factor for late onset non-infectious pulmonary complications diagnosed in the first 36 months after transplantation in an observational prospective cohort study on 198 patients ([@B11]). Therefore, functional pulmonary explorations and long-term surveillance are warranted after community acquired viral infections which occurred early after HCT. To better understand risk factors of pulmonary complications in children after HCT, a multicentric French trial is ongoing^[7](#fn07){ref-type="fn"}^. Early treatment with β2 mimetics and inhaled steroids might be useful and should be proposed in case of persistent obstructive syndrome after respiratory viral infections resolution in HCT recipients.

Concluding Discussion
=====================

This review has limitations because we present results from small case series that have restricted meaningfulness. Further, it includes recommendations that were in part made before the era of T cell repleted haploidentical transplantations. This is an area of intense research and these new developments might impact the epidemiology and outcomes of viral infections after HCT.

Respiratory virus infections continue to cause disease both in the pre-transplant as well as in the post-transplant period and should be taken very seriously, especially in children who tend to shed virus for longer periods. This long shedding time has implications for infection control. Therefore, both personnel and patients and their families should be properly instructed in hand hygiene. In case of pre-transplant infections, HCT should be deferred but the underlying disease, the conditioning regimen and donor availability need to be considered. In pediatric patients who also tend to acquire viruses more frequently, we favor transplant delay in elected cases, even in asymptomatic patients.

Without doubt, disease progression from URI to LRI influences the outcome in HCT recipients. There are a number of risk factors shared by respiratory viruses that are associated with LRI occurrence; lymphopenia appears to be a specific risk factor in this case. Other risk factors shared with increased mortality are steroid use at the time of LRI diagnosis, oxygen requirement at the time of BAL, and severity of disease based on APACHE II score. In addition, myeloablative conditioning, GvHD, bacterial as well as fungal pulmonary co-infections (especially with IFV and PIV infections) seem to worsen the outcome.

Is there a possibility to reduce the risk of progression from URI to LRI? There might be a chance if co-infections can be reduced or diagnosed and treated promptly. These co-infections could be more easily avoided if they were nosocomially acquired by transfer from personnel or visitors. Therefore, people who have access to the patient should be aware of this problem. Also, shortening of the lymphopenic interval could reduce disease progression. This might be achieved with a stricter withdrawal of immunosuppressive drugs, e.g., steroids, or a milder form of conditioning.

Early and specific diagnostics are of the essence. It would be best to obtain diagnostic samples straight from the area of infection, i.e., from BAL material and not a nasal swab in case of a LRI, however, this might be sometimes impractical and not be tolerated by the patient. Unless a specific viral agent is suspected and a single or duplex PCR are ordered, e.g., during an outbreak, novel multiplex assays should be employed that also identify a bacterial co-infection. What is more, novel multiplex assays that are able to quantify viral loads clearly have the potential to help identify which patients are at increased risk and who might need treatment urgently -- particularly since supporting measures like radiological imaging techniques often do not point to a specific pathogen and provide non-specific results with regard to identification of the pathogen responsible. However, while chest x-rays discover inflammatory processes with delay, CT findings might help to differentiate between pathogens. All these diagnostic steps should be carried out after full evaluation of the circumstances and in an orderly fashion. The ISI and the RSI (Tables [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}) might be helpful to identify patients at risk but await validation in clinical trials. Eventually, only few antivirals are available and licensed to treat respiratory virus infections. Several drugs have been tested in HCT recipients and promising results have been published. Novel antiviral compounds are urgently required that might be used in combination with antiviral lymphocytes as currently being developed for CMV, EBV, AdV, or BK antivirus CTLs in US (NCT01945814, NCT01570283) and European international trials (the TRACE trial). The production of these cells should be confined to specialized laboratories, either university-based or commercial, however, they should be easily accessible. The expansion of this approach to target respiratory viruses might be similarly useful to halt disease progression from URI to LRI.

###### 

Immunodeficiency scoring index (ISI) for RSV.

  Criteria                                                                Weighing criteria   Assigned weights (score)
  ----------------------------------------------------------------------- ------------------- --------------------------
  ANC \< 500/μL                                                           \>2.5               3
  ALC \< 200/μL                                                           \>2.5               3
  Age ≥ 40 years                                                          2.0-2.5             2
  Myeloablative conditioning regimen                                      \<2.0               1
  GVHD (acute or chronic)                                                 \<2.0               1
  Corticosteroids within the last 30 days                                 \<2.0               1
  Recent or pre-engraftment allo-HCT                                      \<2.0               1
  Low risk: 0--2 score, moderate risk 3--6 score, high risk 7--12 score                       

ANC, absolute neutrophil count; ALC, absolute lymphocyte count; GVHD, graft-versus-host disease; Modified after

Shah et al. (2014)

.

###### 

Scoring algorithm of the Radiologic Severity Index (RSI).

  Lung zones (3 left lobe, 3 right lobe; 6 total) are evaluated by chest x-ray and CT scan; for each lobe there are three zones: (a) upper (above carina); (b) middle (below carina); (c) lower (below inferior pulmonary vein)                                                                            
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------- ---------------------- -------------------------------------------------
  **Pattern score**                                                                                                                                                                                                               **Predominant radiologic pattern in lung zone**   **Volumetric score**   **Extent of volumetric radiologic involvement**
                                                                                                                                                                                                                                                                                                           
  1                                                                                                                                                                                                                               Normal lung                                       0                      0% (normal)
  2                                                                                                                                                                                                                               Ground-glass opacities                            1                      1--24%
  3                                                                                                                                                                                                                               Consolidation                                     2                      25--49%
                                                                                                                                                                                                                                                                                    3                      50--74%
                                                                                                                                                                                                                                                                                    4                      75--100%

To calculate the RSI score, the predominant pattern for each lung zone is multiplied with the extent of the volumetric radiologic involvement, e.g., if ground-glass opacities are detected in all six lung zones with all having a volumetric score of 3, the RSI score would be 36 (2 × 3 × 6). The maximum score is 72. Modified after

Sheshadri et al. (2018)

.

Finally, the application of CAR T cells to combat respiratory viral infections might be an option in the future, especially in combination with tumor targeting CAR T cells. However, pulmonary toxicity should be considered due to cross-reactivity of CAR T cells with non-targeted proteins, and also ARDS that often occurs in severe LRI might be worsened by cytokine release syndrome. While viral pneumonia still remains a concern in HCT patients, new drug developments, along with sophisticated T cell approaches, should diminish complications caused by respiratory viruses.
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AdV

:   adenovirus

BAL

:   bronchoalveolar lavage

CMV

:   cytomegalovirus

GvHD

:   graft-*versus*-host disease

HBoV

:   human bocavirus

HCoV

:   human coronavirus

HCT

:   hematopoietic cell transplantation

HMPV

:   human metapneumovirus

IFV

:   influenza virus

ISI

:   immunodeficiency scoring index

IVIG

:   intravenous polyvalent immunoglobulins

LRI

:   lower respiratory tract infection

PCR

:   polymerase chain reaction

PIV

:   parainfluenza virus

RhV

:   rhinovirus

RSI

:   radiology severity index

RSV

:   respiratory syncytial virus

URI

:   upper respiratory tract infection
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